全文获取类型
收费全文 | 1117313篇 |
免费 | 75755篇 |
国内免费 | 1540篇 |
专业分类
耳鼻咽喉 | 15357篇 |
儿科学 | 35992篇 |
妇产科学 | 29750篇 |
基础医学 | 159498篇 |
口腔科学 | 30117篇 |
临床医学 | 99575篇 |
内科学 | 212688篇 |
皮肤病学 | 25209篇 |
神经病学 | 86634篇 |
特种医学 | 43975篇 |
外国民族医学 | 201篇 |
外科学 | 166977篇 |
综合类 | 22053篇 |
现状与发展 | 1篇 |
一般理论 | 315篇 |
预防医学 | 79879篇 |
眼科学 | 25114篇 |
药学 | 88903篇 |
7篇 | |
中国医学 | 2887篇 |
肿瘤学 | 69476篇 |
出版年
2021年 | 9520篇 |
2019年 | 9399篇 |
2018年 | 13196篇 |
2017年 | 10152篇 |
2016年 | 11495篇 |
2015年 | 12795篇 |
2014年 | 17149篇 |
2013年 | 24637篇 |
2012年 | 34424篇 |
2011年 | 36143篇 |
2010年 | 20912篇 |
2009年 | 19531篇 |
2008年 | 32681篇 |
2007年 | 34760篇 |
2006年 | 35276篇 |
2005年 | 33440篇 |
2004年 | 31873篇 |
2003年 | 30435篇 |
2002年 | 29149篇 |
2001年 | 60212篇 |
2000年 | 61615篇 |
1999年 | 51124篇 |
1998年 | 12762篇 |
1997年 | 11246篇 |
1996年 | 11215篇 |
1995年 | 10489篇 |
1994年 | 9461篇 |
1993年 | 8965篇 |
1992年 | 37857篇 |
1991年 | 36337篇 |
1990年 | 35799篇 |
1989年 | 34341篇 |
1988年 | 30914篇 |
1987年 | 30020篇 |
1986年 | 28254篇 |
1985年 | 26483篇 |
1984年 | 19231篇 |
1983年 | 16156篇 |
1982年 | 8852篇 |
1979年 | 17046篇 |
1978年 | 11414篇 |
1977年 | 10249篇 |
1976年 | 8846篇 |
1975年 | 10077篇 |
1974年 | 11654篇 |
1973年 | 11281篇 |
1972年 | 10756篇 |
1971年 | 10095篇 |
1970年 | 9252篇 |
1969年 | 8942篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
103.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献104.
105.
Walid K. Abu Saleh Phillip Mason Odeaa Al Jabbari Hany Samir Brian A. Bruckner 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(6):569-571
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support. 相似文献
106.
More than just crushing: a prospective pre‐post intervention study to reduce drug preparation errors in patients with feeding tubes
下载免费PDF全文
![点击此处可从《Journal of clinical pharmacy and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
107.
108.
Clinical Spectrum of Capillary Malformation–Arteriovenous Malformation Syndrome Presenting to a Pediatric Dermatology Practice: A Retrospective Study
下载免费PDF全文
![点击此处可从《Pediatric dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nicole A. Weitz M.D. Christine T. Lauren M.D. Gerald G. Behr M.D. June K. Wu M.D. Jessica J. Kandel M.D. Philip M. Meyers M.D. Sally Sultan M.D. Kwame Anyane‐Yeboa M.D. Kimberly D. Morel M.D. Maria C. Garzon M.D. 《Pediatric dermatology》2015,32(1):76-84
Capillary malformation–arteriovenous malformation syndrome (CM‐AVM) is an autosomal dominant disorder caused by RASA1 mutations. The prevalence and phenotypic spectrum are unknown. Evaluation of patients with multiple CMs is challenging because associated AVMs can be life threatening. The objective of this study was to describe the clinical characteristics of children presenting with features of CM‐AVM to an academic pediatric dermatology practice. After institutional review board approval was received, a retrospective chart review was performed of patients presenting between 2009 and 2012 with features of CM‐AVM. We report nine cases. Presenting symptoms ranged from extensive vascular stains and cardiac failure to CMs noted incidentally during routine skin examination. All demonstrated multiple CMs, two had Parkes Weber syndrome, and two had multiple infantile hemangiomas. Seven patients had family histories of multiple CMs; three had family histories of large, atypical CMs. Six had personal or family histories of AVMs. Genetic evaluation was recommended for all and was pursued by six families; four RASA1 mutations were identified, including one de novo. Consultations with neurology, cardiology, and orthopedics were recommended. Most patients (89%) have not required treatment to date. CM‐AVM is an underrecognized condition with a wide clinical spectrum that often presents in childhood. Further evaluation may be indicated in patients with multiple CMs. This study is limited by its small and retrospective nature. 相似文献
109.
110.